#Obesity #GLP1 #AstraZeneca #PharmaceuticalIndustry #ClinicalResearch #Innovation #CardiometabolicHealth #Healthcare #DrugDevelopment #LifeSciences AstraZeneca Expands into Obesity with Oral GLP-1 Therapy AstraZeneca Expands into the Obesity Space The obesity treatment landscape continues to evolve rapidly, and AstraZenecas positive Phase II results for its oral GLP-1 therapy represent an important milestone
Amylin exerts osteogenic actions with different efficacy depending on the diabetic status
Circulation 133:689691 Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, CVD-REAL Investigators and Study Group et al (2018) Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
LiPo Battery Accessories There are a number of accessories that you can purchase to make using and maintaining LiPo batteries a lot easier
This combination ensures superior absorption of active ingredients, delivering deep hydration and nourishment to the skin